

09912774

(FILE 'HOME' ENTERED AT 14:16:11 ON 18 AUG 2004)

FILE 'REGISTRY' ENTERED AT 14:17:17 ON 18 AUG 2004
L1 1 S ELETRIPTAN/CN

FILE 'CAPLUS, CA, USPAT2, USPATFULL' ENTERED AT 14:19:51 ON 18 AUG 2004
L2 314 S L1
L3 10175 S EUDRAGIT
L4 212378 S PLASTICIZER
L5 5 S L2 AND L3
L6 3 DUP REM L5 (2 DUPLICATES REMOVED)
L7 29590 S ACRYLIC (W) COPOLYMER
L8 3 S L7 AND L2

blessing

09912774

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2002:107079 CAPLUS
DOCUMENT NUMBER: 136:156442
TITLE: Particulate composition of eletriptan showing a sigmoidal pattern of controlled release
INVENTOR(S): De Raspide, Manaud Pierre Frederick; MacRae, Ross James; Walther, Mathias
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer, Inc.
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002009675	A1	20020207	WO 2001-IB1279	20010718
WO 2002009675	C2	20030710		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
BR 2001012839	A	20030624	BR 2001-12839	20010718
EP 1365748	A2	20031203	EP 2001-949819	20010718
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004505034	T2	20040219	JP 2002-515228	20010718
US 2002034545	A1	20020321	US 2001-912774	20010725
BG 107361	A	20030630	BG 2002-107361	20021206
HR 2003000036	A1	20030430	HR 2003-36	20030121
NO 2003000498	A	20030131	NO 2003-498	20030131
PRIORITY APPLN. INFO.:			GB 2000-18968	A 20000802
			US 2000-225237P	P 20000815
			WO 2001-IB1279	W 20010718

AB The invention provides a pharmaceutical composition in particulate form, suitable for oral administration, including a core containing eletriptan or a pharmaceutically acceptable salt thereof, the core being coated with a water-insol., permeable coating including one or more acrylic copolymer(s) containing trimethylammoniummethacrylate groups, said composition being capable of achieving a sigmoidal pattern of controlled drug release. Such a pharmaceutical composition is particularly useful in the prevention of migraine recurrence. Drug cores were made from a mixture containing eletriptan hydrobromide 1455.0, microcryst. cellulose 773.0, lactose 773.0, and water 1400 g. The cores were coated with a dispersion containing talc 20.0, water 331.7, tri-Et citrate 8.0, **Eudragit** RS30D 126.7, **Eudragit** RL30D 6.7 g and dried. The particles thus obtained had size distribution of 0.71-1.4 mm. In vitro and in vivo release of eletriptan was studied.

L6 ANSWER 2 OF 3 USPAT2 on STN DUPLICATE 2
ACCESSION NUMBER: 2002:185318 USPAT2
TITLE: Process for manufacturing coated granules with masked

blessing

09912774

INVENTOR(S) : taste and immediate release of the active principle
Nouri, Noureddine, Cannes, FRANCE
Zuccarelli, Jean-Marc, Antibes, FRANCE
Chauveau, Charles, Valbonne, FRANCE
Bruna, Etienne, Jouy, FRANCE
PATENT ASSIGNEE(S) : Ethypharm, Houdan, FRANCE (non-U.S. corporation)

PATENT INFORMATION: US 6660382 B2 20031209
APPLICATION INFO.: US 2002-41389 20020108 (10)
RELATED APPLN. INFO.: Continuation of Ser. No. WO 2000-FR1855, filed on 30 Jun 2000

NUMBER DATE

PRIORITY INFORMATION: FR 1999-9047 19990708
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Killiman, Leszek
LEGAL REPRESENTATIVE: Heslin Rothenberg Farley & Mesiti P.C.
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 602

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns a method for making coated granules with masked taste and instant release of the active principle which consists in: first, mixing the constituents of a powder comprising at least the active principle and a granular disintegrating agent; then, granulating the resulting powder, in the presence of a mixture of carriers comprising at least a binding agent capable of binding the particles together to obtain grains; coating the grains formed by spraying a suspension comprising at least a coating agent and a membrane disintegrating agent; finally drying the resulting coated granules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 3 OF 3 USPATFULL on STN
ACCESSION NUMBER: 2002:60711 USPATFULL
TITLE: Particulate composition of eletriptan
INVENTOR(S) : De Raspide, Manaud Pierre Frederic, Sandwich, UNITED KINGDOM
Macrae, Ross James, Sandwich, UNITED KINGDOM
Walther, Mathias, Sandwich, UNITED KINGDOM

NUMBER DATE

PATENT INFORMATION: US 2002034545 A1 20020321
APPLICATION INFO.: US 2001-912774 A1 20010725 (9)

NUMBER DATE

PRIORITY INFORMATION: GB 2000-18968 20000802
DOCUMENT TYPE: US 2000-225237P 20000815 (60)
FILE SEGMENT: Utility
LEGAL REPRESENTATIVE: APPLICATION
Paul H. Ginsburg, Pfizer Inc, 20th Floor, 235 East 42nd Street, New York, NY, 10017-5755

blessing

09912774

NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 763

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a pharmaceutical composition in particulate form, suitable for oral administration, including a core containing eletriptan or a pharmaceutically acceptable salt thereof, the core being coated with a water-insoluble, permeable coating including one or more acrylic copolymer(s) containing trimethylammoniummethylmethacrylate groups, said composition being capable of achieving a sigmoidal pattern of controlled drug release. Such a pharmaceutical composition is particularly useful in the prevention of migraine recurrence.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

blessing

09912774

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 143322-58-1 REGISTRY
CN 1H-Indole, 3-[(2R)-1-methyl-2-pyrrolidinyl]methyl]-5-[2-(phenylsulfonyl)ethyl]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-Indole, 3-[(1-methyl-2-pyrrolidinyl)methyl]-5-[2-(phenylsulfonyl)ethyl]-, (R)-
OTHER NAMES:
CN (R)-5-[2-(Benzenesulfonyl)ethyl]-3-[(N-methylpyrrolidin-2-yl)methyl]-1H-indole
CN **Eletriptan**
CN UK 116044
FS STEREOSEARCH
MF C22 H26 N2 O2 S
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CIN, DDFU, DIOGENES, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PHAR, PROMT, PROUSDDR, PS, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

130 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
131 REFERENCES IN FILE CAPLUS (1907 TO DATE)


blessing

09912774

=> d scan

L1 1 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1H-Indole, 3-[(2R)-1-methyl-2-pyrrolidinyl]methyl]-5-[2-(phenylsulfonyl)ethyl]- (9CI)
MF C22 H26 N2 O2 S
CI COM

Absolute stereochemistry. Rotation (+).



blessing

WEST Search History

[Hide Items](#) | [Restore](#) | [Clear](#) | [Cancel](#)

DATE: Wednesday, August 18, 2004

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>			
<input type="checkbox"/>	L11	l5 and l8	8
<input type="checkbox"/>	L10	l5 and l7	2
<input type="checkbox"/>	L9	L8 and l7	209
<input type="checkbox"/>	L8	eudragit	2856
<input type="checkbox"/>	L7	L6	19372
<input type="checkbox"/>	L6	acrylic copolymer	19372
<input type="checkbox"/>	L5	eletriptan	146
<input type="checkbox"/>	L4	WO-200006161\$.did.	1
<input type="checkbox"/>	L3	WO-20006161\$.did.	10
<input type="checkbox"/>	L2	WO-0006161\$.did.	0
<input type="checkbox"/>	L1	5112621.pn.	2

END OF SEARCH HISTORY

WEST Search History

[Hide Items](#) [Restore](#) [Clear](#) [Cancel](#)

DATE: Wednesday, August 18, 2004

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>			
<input type="checkbox"/>	L10	L9 and l6	7
<input type="checkbox"/>	L9	L8 and l1	20
<input type="checkbox"/>	L8	L7 and l2	67
<input type="checkbox"/>	L7	eletriptan	146
<input type="checkbox"/>	L6	L5 same coat\$3	6948
<input type="checkbox"/>	L5	L4 or l3	22019
<input type="checkbox"/>	L4	eudragit	2856
<input type="checkbox"/>	L3	acrylic copolymer	19372
<input type="checkbox"/>	L2	particle	1411704
<input type="checkbox"/>	L1	core	1064135

END OF SEARCH HISTORY